Recent Updates
Recently added Catalysts

Simpliciti Shoulder System

Phase 3

Primary Generalized (Osteo)Arthritis | Unknown | Musculoskeletal |Stryker Corporation|Last Updated: Apr 25, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment157

FDA Designations

No designations recorded

Clinical trial landscape

Simpliciti Shoulder System · 1 trial · 2 indications

Phase 3 1
NCT01390038Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder ArthroplastyPrimary Generalized (Osteo)Arthritis
COMPLETED157 Analytics
PHASE3COMPLETED
Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty
Primary Generalized (Osteo)ArthritisUnlock trial analytics

Study Endpoints

Primary Endpoints

Device Success Rate
24 months

A subject is a Patient Success at 24-months if: 1. There is NO continuous radiolucent line around the prosthesis; and 2. The adjusted Constant Score is \> 85 (successful outcome); and 3. They did not have revision surgery; and 4. They did not have a system-related serious adverse event.

Secondary Endpoints

Quality of Life
24 months
Range of Motion
24 months
Strength
24 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Simpliciti™ Shoulder SystemEXPERIMENTALThe Simpliciti™ Shoulder System is intended for Total Shoulder Arthroplasty of the shoulder.

Interventions

NameTypeDescription
Simpliciti™ Shoulder SystemDEVICETotal shoulder arthroplasty system
Unlock Study Design Details

Eligibility Criteria

Age Range22 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites14

Inclusion Criteria: * Adult subject 22 years or older * Clinical indication for total shoulder replacement due to primary diagnosis of arthritis. Primary arthritis for this study includes osteoarthritis, and/or traumatic arthritis. * Scapula and proximal humerus must have reached skeletal maturity ...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Simpliciti Shoulder System

What is the Simpliciti Shoulder System used for?

The Simpliciti Shoulder System is used for primary generalized (osteo)arthritis of the shoulder, as well as post-traumatic arthrosis of the upper arm joints. It is a device designed for total shoulder arthroplasty, specifically replacing the humeral head. The system is intended for patients aged 22 years and older.

Who makes the Simpliciti Shoulder System?

The Simpliciti Shoulder System is developed by Stryker Corporation, a medical technology company. Stryker is publicly traded on the New York Stock Exchange under the ticker symbol SYK. The company is responsible for the design, manufacturing, and clinical development of this shoulder replacement system.

What phase is the Simpliciti Shoulder System in?

The Simpliciti Shoulder System is in Phase 3 clinical development. It has completed one Phase 3 clinical trial, which was an Investigational Device Exemption (IDE) study. The device is investigational and not yet approved for commercial use, as it is still undergoing clinical evaluation to establish its safety and effectiveness.

What clinical trials is the Simpliciti Shoulder System in?

The Simpliciti Shoulder System has been studied in one clinical trial, identified as NCT01390038. This trial, titled 'Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty,' was a Phase 3 study that has been completed. The trial enrolled 157 participants in the United States and included healthy volunteers.

How does the Simpliciti Shoulder System work?

The Simpliciti Shoulder System works by replacing the humeral head, the ball portion of the shoulder joint, during total shoulder arthroplasty. This procedure is designed to treat conditions such as primary generalized osteoarthritis and post-traumatic arthrosis. The system aims to restore shoulder function and alleviate pain associated with these degenerative joint conditions.